Human Stem Cell Transplantation for Retinal Degenerative Diseases: Where Are We Now?

Medicina (Kaunas). 2022 Jan 10;58(1):102. doi: 10.3390/medicina58010102.

Abstract

Background and Objectives: Irreversible visual impairment is mainly caused by retinal degenerative diseases such as age-related macular degeneration and retinitis pigmentosa. Stem cell research has experienced rapid progress in recent years, and researchers and clinical ophthalmologists are trying to implement this promising technology to treat retinal degeneration. The objective of this systematic review is to analyze currently available data from clinical trials applying stem cells to treat human retinal diseases. Materials and Methods: We performed a systematic literature search in PubMed to identify articles related with stem cell therapies to retinal diseases published prior to September 2021. Furthermore, a systematic search in ClinicalTrials (NIH U.S. National Library of Medicine) was performed to identify clinical trials using stem cells to treat retinal diseases. A descriptive analysis of status, conditions, phases, interventions, and outcomes is presented here. Conclusions: To date, no available therapy based on stem cell transplantation is approved for use with patients. However, numerous clinical trials are currently finishing their initial phases and, in general, the outcomes related to implantation techniques and their long-term safety seem promising. In the next few years, we expect to see quantifiable results pertaining to visual function improvement.

Keywords: clinical trial; retina; stem cells; transplantation.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Macular Degeneration* / therapy
  • Retina
  • Retinal Degeneration* / therapy
  • Stem Cell Transplantation
  • United States